J&J Biosurgery Collaboration Evolves Into $438 Million Acquisition Of Omrix
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson will expand its presence in the biologic-based, active hemostat market through the $438 million purchase of Omrix Biopharmaceuticals, announced Nov. 24